Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420169 | 0.92 | MCL1 (0.42) | PTGDR2SMN1; SMN2TSHRNPSR1LMNA | |
| SCHEMBL6419314 | 0.92 | PTGDR2 (0.48) | PTGDR2SMN1; SMN2TSHRMAPTHCRTR1 | |
| SCHEMBL6422394 | 0.91 | MEN1 (0.44) | SMN1; SMN2TSHRNPSR1LMNAMAPT | |
| SCHEMBL6419409 | 0.91 | PTGDR2 (0.41) | PTGDR2SMN1; SMN2TSHRNPSR1LMNA | |
| SCHEMBL6420269 | 0.89 | PTGDR2 (0.43) | PTGDR2SMN1; SMN2TSHRNPSR1LMNA | |
| SCHEMBL6420553 | 0.83 | MCL1 (0.45) | PTGDR2TSHRLMNAMAPTMEN1 | |
| SCHEMBL6420215 | 0.83 | PTGDR2 (0.44) | PTGDR2SMN1; SMN2TSHRNPSR1LMNA | |
| SCHEMBL6420251 | 0.82 | MEN1 (0.46) | PTGDR2TSHRLMNAMAPTMEN1 | |
| SCHEMBL6423531 | 0.81 | MCL1 (0.41) | SMN1; SMN2TSHRNPSR1LMNAMAPT | |
| SCHEMBL6420023 | 0.80 | PTGDR2 (0.39) | PTGDR2SMN1; SMN2TSHRNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | PTGDR2 1670/4885SMN1; SMN2 66/4885TSHR 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.